ClinicalTrials.gg
CompletedNCT00329836Updated Feb 28, 2025Results posted

A Research Study to Examine Cutaneous Allodynia and Cluster Headache

An observational study in Cluster Headache, sponsored by Thomas Jefferson University. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-02-28.

Sponsored by Thomas Jefferson University · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
41
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a research study examining cutaneous allodynia and cluster headaches. Cutaneous allodynia means the feeling of pain or unpleasant sensation when normally non-painful stimuli (e.g. light touch) are applied to the skin. Many studies have been performed looking at the presence of cutaneous allodynia in patients with migraines; however, few studies have examined it in cluster headache patients. There is still much to be learned about the brain and how it functions if the investigators are to understand the underlying causes of cluster headache. It is important to explore cutaneous allodynia in cluster headache as it may help guide physicians with the care of these individuals. Sixty patients will be screened for this study. Thomas Jefferson University is the only center enrolling patients in this research study.

02

Conditions studied

  • Cluster Headache

Browse trials for

03

In context

Cluster Headache

123 studies on the registry are indexed under Cluster Headache; 26 are open to participants now.

This study's enrollment of 41 is below the median of 68 across 32 observational studies indexed under Cluster Headache.

Browse Cluster Headache studies →

Lead sponsor

Thomas Jefferson University is the lead sponsor of 393 studies on the registry; 70 are open to participants now.

Of its 45 completed or terminated interventional studies of FDA-regulated products, 21 (47%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Subjects with cluster headache

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female patients aged 18-75, inclusive
  • Diagnosis of cluster headache, episodic or chronic.
  • Patients with episodic CH can be either in active cluster period or not.
  • Ability to read and understand an form, where the study protocol is described.

Exclusion criteria

Exclusion Criteria:

  • Patients with abnormal sensory findings on examination, or any known neurological disease that may affect skin sensation (peripheral neuropathy, multiple sclerosis, stroke, etc).
  • Patients who are cognitively impaired, as determined by investigator
  • Patients with significant psychiatric disorder that may affect their understanding of the study protocol and/or their cooperation with the investigators.
  • Patients who had taken an acute pain medication within 24 hours prior to allodynia testing.
  • Patients with skin diseases that may cause abnormal skin sensation.
  • Patients who had been treated with a nerve block in the 4 week period prior to allodynia testing
  • Patients who had been treated with Botulinum neurotoxin within the 4 month period prior to allodynia testing
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
41 participants (actual)

Groups and cohorts

  • Subjects with cluster headache

    Subjects with both episodic and chronic cluster (as defined by the International Headache Society-IHS) were enrolled.

    Other: There are no interventions in the observational study. The symptom of allodynia was measured.

Interventions

  • OtherThere are no interventions in the observational study. The symptom of allodynia was measured.

    No intervention. Description of allodynia testing appears elsewhere in this document

06

What researchers measure

Primary outcomes

  1. Prevalence of Allodynia in Subjects With Cluster Headache

    Allodynia (discomfort to normal sensation) was assessed by brushing at constant rate of 2 brushes/sec and pressure allodynia with Von Frei hairs. Outcome (discomfort) was measured on a 100 mm visual analogue scale.

    Time frame: Allodynia was assessed at the screening visit

07

Results

Posted Aug 16, 2011

Participant flow

Subjects with cluster headache recruited from Jefferson Headache Center office practice or community. First subject enrolled 7/5/05. Last subject enrolled 6/9/06.

Participant flow — Overall Study
MilestoneSubjects With Cluster Headache
Started41
Completed41
Not completed0

Outcome measures

PrimaryPrevalence of Allodynia in Subjects With Cluster Headache

Allodynia (discomfort to normal sensation) was assessed by brushing at constant rate of 2 brushes/sec and pressure allodynia with Von Frei hairs. Outcome (discomfort) was measured on a 100 mm visual analogue scale.

Time frame:
Allodynia was assessed at the screening visit
Reported as:
Number · participants
Prevalence of Allodynia in Subjects With Cluster Headache
participantsSubjects With Cluster Headache
Prevalence of Allodynia in Subjects With Cluster Headache20

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Subjects With Cluster Headache—0/41 (0%)0/41 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Subjects With Cluster Headache
<=18 years0
Between 18 and 65 years41
>=65 years0
Age, Continuous
Age, Continuous(years)Subjects With Cluster Headache
Mean44.9 ± 10.5
Sex: Female, Male
Sex: Female, Male(Participants)Subjects With Cluster Headache
Female19
Male22
Region of Enrollment
Region of Enrollment(participants)Subjects With Cluster Headache
United States41
08

Study locations

1 site
  • Jefferson Headache Center/ Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00329836
Responsible party
Stephen D. Silberstein (Professor of Neurology, Thomas Jefferson University) — Principal investigator
First posted
May 25, 2006
Start date
Aug 2006
Primary completion
Feb 2008
Completion
Feb 2008
Results posted
Aug 16, 2011
Last update
Feb 28, 2025

Study contacts

Abraham A. Ashkenazi, M.D.
principal investigator · Jefferson Headache Center/ thomas Jefferson University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion